Quince Therapeutics (QNCX) Stock Overview
A biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
QNCX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Quince Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.14 |
| 52 Week High | US$2.45 |
| 52 Week Low | US$0.72 |
| Beta | 1.15 |
| 1 Month Change | 21.59% |
| 3 Month Change | 35.44% |
| 1 Year Change | 9.18% |
| 3 Year Change | 194.68% |
| 5 Year Change | -95.67% |
| Change since IPO | -93.49% |
Recent News & Updates
Recent updates
Is Quince Therapeutics (NASDAQ:QNCX) Using Too Much Debt?
Oct 07
Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026
May 15Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex
Aug 20Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation
Nov 21Cortexyme to change name and ticker symbol next month
Jul 27Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
Mar 01Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
Dec 15We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate
Dec 15Cortexyme: A Challenging Path Forward
Nov 17Cortexyme: Positive Lessons To Be Learned From Disappointing Results
Nov 01Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease
Oct 11Cortexyme: Alzheimer's Readout In November A Binary Event
Sep 12We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth
Aug 23Shareholder Returns
| QNCX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 27.4% | 1.6% | -2.1% |
| 1Y | 9.2% | 16.2% | 9.4% |
Return vs Industry: QNCX underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: QNCX matched the US Market which returned 9.4% over the past year.
Price Volatility
| QNCX volatility | |
|---|---|
| QNCX Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QNCX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: QNCX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 36 | Dirk Thye | www.quincetx.com |
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions.
Quince Therapeutics, Inc. Fundamentals Summary
| QNCX fundamental statistics | |
|---|---|
| Market cap | US$119.16m |
| Earnings (TTM) | -US$56.98m |
| Revenue (TTM) | n/a |
Is QNCX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QNCX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$56.98m |
| Earnings | -US$56.98m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 1,654.4% |
How did QNCX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/23 01:32 |
| End of Day Share Price | 2025/11/21 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Quince Therapeutics, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Kumaraguru Raja | Brookline Capital Markets |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |